Future studies should also consider including drugs such as encenicline, an α7-nicotinic receptor partial agonist with 5HT3 antagonist effects [62, 63], and CVN058, a novel selective 5HT3 antagonist [64], which are also of interest as adjunctive treatments for patients with schizophrenia. The gene discussed is HTR3A; the disease is schizophrenia.